TY - JOUR
T1 - Vaccination strategies against Zika virus
AU - Fernandez, Estefania
AU - Diamond, Michael S.
N1 - Funding Information:
NIH grants (R01 AI073755 and R01 AI104972) to M.S.D supported this work. E.F. was supported by an NIH Pre-doctoral training grant award (T32 AI007163).
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - The epidemic emergence of Zika virus (ZIKV) in 2015–2016 has been associated with congenital malformations and neurological sequela. Current efforts to develop a ZIKV vaccine build on technologies that successfully reduced infection or disease burden against closely related flaviviruses or other RNA viruses. Subunit-based (DNA plasmid and modified mRNA), viral vectored (adeno- and measles viruses) and inactivated viral vaccines are already advancing to clinical trials in humans after successful mouse and non-human primate studies. Among the greatest challenges for the rapid implementation of immunogenic and protective ZIKV vaccines will be addressing the potential for exacerbating Dengue virus infection or causing Guillain–Barré syndrome through production of cross-reactive immunity targeting related viral or host proteins. Here, we review vaccine strategies under development for ZIKV and the issues surrounding their usage.
AB - The epidemic emergence of Zika virus (ZIKV) in 2015–2016 has been associated with congenital malformations and neurological sequela. Current efforts to develop a ZIKV vaccine build on technologies that successfully reduced infection or disease burden against closely related flaviviruses or other RNA viruses. Subunit-based (DNA plasmid and modified mRNA), viral vectored (adeno- and measles viruses) and inactivated viral vaccines are already advancing to clinical trials in humans after successful mouse and non-human primate studies. Among the greatest challenges for the rapid implementation of immunogenic and protective ZIKV vaccines will be addressing the potential for exacerbating Dengue virus infection or causing Guillain–Barré syndrome through production of cross-reactive immunity targeting related viral or host proteins. Here, we review vaccine strategies under development for ZIKV and the issues surrounding their usage.
UR - http://www.scopus.com/inward/record.url?scp=85017646438&partnerID=8YFLogxK
U2 - 10.1016/j.coviro.2017.03.006
DO - 10.1016/j.coviro.2017.03.006
M3 - Review article
C2 - 28432975
AN - SCOPUS:85017646438
SN - 1879-6257
VL - 23
SP - 59
EP - 67
JO - Current Opinion in Virology
JF - Current Opinion in Virology
ER -